EUVIMEDEUVIMED entdecken
Crossref

The Survival Benefit of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in the Management of Breast Cancer

Ruoyang Li, Xuewei Zhao, Yunfei Huang, Chunxiao Li, Lei Liu, Meiqi Wang, Jiaxing Wang, Zhenchuan Song iD

Cancer Biotherapy and Radiopharmaceuticals · 2024

DOI: 10.1089/cbr.2024.0011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, 2024. Verfasst von Ruoyang Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Doxorubicin, Breast Neoplasms, Polyethylene Glycols, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinBreast NeoplasmsPolyethylene GlycolsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleNeoadjuvant TherapyMiddle AgedAdultAgedEpirubicinDisease-Free SurvivalPrognosisAntibiotics, AntineoplasticChemotherapy, Adjuvant

Stichwörter der Autor:innen

breast cancercardiac toxicitydisease-free survivalneoadjuvant chemotherapyoverall survivalpegylated liposomal doxorubicin

Substanzen

Doxorubicinliposomal doxorubicinPolyethylene GlycolsEpirubicinAntibiotics, Antineoplastic

Autor:innen und Institutionen

  • Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Department of Medicine, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

ORCID-Profile: Zhenchuan Song

Zitieren

APA

Li, R., Zhao, X., Huang, Y., Li, C., Liu, L., Wang, M., Wang, J., & Song, Z. (2024). The Survival Benefit of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in the Management of Breast Cancer. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.2024.0011

Vancouver

Li R, Zhao X, Huang Y, Li C, Liu L, Wang M, et al. The Survival Benefit of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in the Management of Breast Cancer. Cancer Biotherapy and Radiopharmaceuticals. 2024. doi:10.1089/cbr.2024.0011

BibTeX
@article{Li2024,
  author = {Li, Ruoyang and Zhao, Xuewei and Huang, Yunfei and Li, Chunxiao and Liu, Lei and Wang, Meiqi and Wang, Jiaxing and Song, Zhenchuan},
  title = {The Survival Benefit of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in the Management of Breast Cancer},
  journal = {Cancer Biotherapy and Radiopharmaceuticals},
  year = {2024},
  doi = {10.1089/cbr.2024.0011}
}
Kostenlos starten →